ライフサイエンスコーパス: cerebral atrophy

1 individuals reveals delay in myelination and cerebral atrophy.

2 the patient's epileptic phenotype as well as cerebral atrophy.

3 iable cerebellar atrophy and highly variable cerebral atrophy.

4 nt of overt clinical symptoms and detectable cerebral atrophy.

5 eased CSF tau and structural MRI measures of cerebral atrophy.

6 quantitative MRI indices suggesting greater cerebral atrophy.

7 tter high signal, and the notable absence of cerebral atrophy.

8 and 57% following correction for effects of cerebral atrophy.

9 were highly correlated with Braak stage and cerebral atrophy.

10 ge, peripheral neuropathy, hearing loss, and cerebral atrophy.

11 which was significantly correlated with age, cerebral atrophy and ADC stage and (b) the striatum, whi

12 the development of LE with its potential for cerebral atrophy and cognitive impairment.

13 re, MSIS-29 (psychological) and EDSS and MRI cerebral atrophy and MTR.

14 However, varying degrees of cerebral atrophy and residual cognitive impairment were

15 thy consistently associated with progressive cerebral atrophy and variable involvement of the white m

16 oundary shift integral to determine rates of cerebral atrophy and ventricular expansion in six patien

17 Patients with PSP had a rate of cerebral atrophy and ventricular expansion of 1.3 and 7.

18 5, and included multifocal hyperintensities, cerebral atrophy, and confluent cortical and subcortical

19 ount for the remaining difference, including cerebral atrophy, and enhanced vasoconstrictor and blunt

20 ephaly, intellectual disability, progressive cerebral atrophy, and intractable seizures.

21 development of motor deficits, weight loss, cerebral atrophy, and neuronal intranuclear inclusions i

22 NS) has been shown to improve memory, reduce cerebral atrophy, and reverse neurodegeneration.

23 However, unlike the latter, the patterns of cerebral atrophy associated with DLB have not been well

24 to quantify the severity and distribution of cerebral atrophy by using automated volumetric analysis

25 lated synaptic loss, in turn contributing to cerebral atrophy, cognitive decline, and increased risk

26 There is an age-related cerebral atrophy, demyelination of the corpus callosum,

27 indicative of a disease-specific pattern of cerebral atrophy for the HIV+ patients.

28 The extent and magnitude of the cerebral atrophy further progressed by the time the subj

29 multiple MRI scans to measure progression of cerebral atrophy in 12 patients with Alzheimer's disease

30 ed resolution of early lesions in 8 and mild cerebral atrophy in 2.

31 CT and MRI showed mild to moderate cerebral atrophy in 4 patients.

32 The extent to which cerebral atrophy in Alzheimer's disease changes with tim

33 g brain imaging technologies have identified cerebral atrophy in diabetic patients, suggesting that t

34 study was to identify a signature pattern of cerebral atrophy in DLB and to compare it with the patte

35 s important information about the pattern of cerebral atrophy in Parkinson's disease and PDD.

36 needed to detect the effects of treatment on cerebral atrophy in this population of patients with adv

37 tment reduces, by as much as seven fold, the cerebral atrophy in those gray matter (GM) regions speci

38 Cerebral atrophy is a correlate of clinical progression

39 Cerebral atrophy is a correlate of clinical progression

40 rrect for the dilution effect of age-related cerebral atrophy may confound interpretation of previous

41 ontal cortex, we showed that neither diffuse cerebral atrophy nor neocortical thickness explained the

42 tensities, microbleeds, microinfarctions and cerebral atrophy on magnetic resonance imaging scans.

43 ntrol group, the SLE patients more often had cerebral atrophy on MRI (32% versus 0%), confirmed by an

44 tional study was to establish the pattern of cerebral atrophy on MRI in Parkinson's disease patients

45 on scanning, whereas all other scans showed cerebral atrophy only.

46 this study was to assess the progression of cerebral atrophy over multiple serial MRI during the per

47 ciated pathologies segregated based on their cerebral atrophy profiles, according to the following sc

48 imilar phenotypes typified by cerebellar and cerebral atrophy, seizures, irritability, ataxia, and ex

49 type that was consistent with cerebellar and cerebral atrophy that could be rescued by wild-type, but

50 a VPS53 allele causing progressive cerebello-cerebral atrophy type 2 (PCCA2) in humans exhibits simil

51 nd corrected for partial-volume effects from cerebral atrophy using an MR-based algorithm.

52 rtunity to assess the impact of treatment on cerebral atrophy using serial MRI.

53 abnormalities, abnormal cortical formation, cerebral atrophy, ventriculomegaly, hydrocephaly, and ce

54 .001); in infants who subsequently developed cerebral atrophy versus those who did not: 7.23 (SD, 0.1

55 ion of surgical pathology, signal change and cerebral atrophy visible on structural MRI can be used t

56 scle biopsy revealed ragged red fibers; mild cerebral atrophy was evident by magnetic resonance imagi

57 mer's disease is associated with progressive cerebral atrophy, which can be seen on MRI with high res